Critical Therapeutics, Inc. Announces Decision To Discontinue Phase II Clinical Trial Of CTI-01
LEXINGTON, Mass.--(BUSINESS WIRE)--March 15, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases, today announced it has decided to discontinue the Phase II clinical trial of CTI-01, an anti-inflammatory compound.